Switching from one CD20-targeting therapy to another doesn't alter their ability to lower disease activity and slow ...

This budget law is nothing but cruel. They threw billions at tax breaks for the wealthy without blinking, but keeping Arizonans with disabilities alive is too expensive.

As drug companies increasingly adopt the DTC sales model, patients will gain the ability to buy the medicines they need at ...

Halozyme Therapeutics reports a record Q2 2025, with 41% revenue growth. Discover raised guidance, strong catalysts, and shareholder-focused initiatives.

Women in their childbearing years are significantly less likely than men in the same age range to be given disease-modifying ...

VANCOUVER, BC, Aug. 7, 2025 /CNW/ - Teresa Alfeld, a filmmaker who was recently diagnosed with multiple sclerosis (MS), is calling for the provincial ...

For the second quarter, total revenues increased 9% to $9.2 billion in comparison to the second quarter of 2024. Product sales grew 9%, driven by 13% volume g ...

Eli Lilly is to buy the private biotech Disarm Therapeutics, which is working on a new class of disease-modifying drugs for neurological diseases, in a deal worth up to $1.36 billion.

Schinecker said that Vabysmo has “already become our strongest growth driver just a year after its launch,” backed up by multiple sclerosis therapy Ocrevus (ocrelizumab), Hemlibra (emicizumab ...